Study guide
19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways
Key Takeaways Explain This Topic AI
Acute nociception progresses through four sequential physiological processes: Transduction (activation of A-delta and C fibers by tissue injury mediators), Transmission (dorsal horn Laminae I/II synapse via glutamate and substance P, ascending spinothalamic tract), Modulation (descending periaqueductal gray and rostral ventromedial medulla monoaminergic inhibition), and Perception.
Repetitive, high-frequency C-fiber nociceptive input generates 'wind-up' in dorsal horn wide dynamic range neurons, removing the magnesium channel block from NMDA receptors to induce central sensitization; subanaesthetic ketamine acts as a non-competitive NMDA receptor antagonist to abort this process.
Systemic intravenous lidocaine (1-1.5 mg/kg bolus followed by 1.5-2 mg/kg/h) was thought to speed bowel recovery after colorectal surgery, but the ALLEGRO trial (JAMA 2025) found no improvement in return of gut function at 72 hours compared with placebo.
Routine continuous basal opioid infusions in patient-controlled analgesia (PCA) are strictly contraindicated in opioid-naive patients due to high risk of severe nocturnal hypoxemia and fatal respiratory depression; standardized sedation monitoring must be prioritized as somnolence reliably precedes respiratory arrest.
Enhanced Recovery After Surgery (ERAS) pathways attenuate the neuroendocrine surgical stress response through preoperative carbohydrate loading, goal-directed fluid therapy, multimodal opioid-sparing analgesia, and aggressive avoidance of prolonged fasting, drains, and immobility.
Last updated: October 2026
19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways
Effective postoperative pain management has evolved from reactive, intermittent opioid monotherapy into proactive, mechanistic multimodal analgesia integrated within Enhanced Recovery After Surgery (ERAS) pathways. Unrelieved acute surgical pain is not merely distressing to the patient; it triggers a profound neuroendocrine stress response (accelerating catabolism, tachycardia, myocardial oxygen consumption, hypercoagulability, and immunosuppression) and drives neuroplastic remodeling that can transition into debilitating chronic postsurgical pain (CPSP).
1. Neurobiology of Nociceptive Pain and Sensitization
Nociception is the physiological neural process of encoding noxious stimuli, progressing through four distinct phases: +------------------------------------------------------------------------------------------------------+
- | THE FOUR PHASES OF THE NOCICEPTIVE PATHWAY |
- | |
- | 1. TRANSDUCTION Primary nociceptors (A-delta & C fibers) convert noxious thermal, mechanical, |
- | or chemical stimuli into action potentials via TRPV1, ASIC, Nav1.7/1.8/1.9. |
- | Inflammatory soup: Bradykinin, PGE2, Substance P, H+, Cytokines. |
- | | |
- | v |
- | 2. TRANSMISSION Propagation along primary afferents to spinal dorsal horn (Laminae I & II |
- | Substantia Gelatinosa). Decussation in anterior white commissure; ascent via |
- | Spinothalamic Tract to VPL thalamus and sensory cortex. |
- | | |
- | v |
- | 3. MODULATION Descending inhibitory pathways originating from Periaqueductal Gray (PAG) |
- | and Rostral Ventromedial Medulla (RVM) release Serotonin (5-HT), |
- | Norepinephrine (alpha-2 receptors), and Endogenous Opioids. |
- | | |
- | v |
- | 4. PERCEPTION Conscious awareness and affective-emotional integration of pain within the |
- | Somatosensory Cortex (S1/S2), Insular Cortex, and Anterior Cingulate Cortex. |
- +------------------------------------------------------------------------------------------------------+
- The Four Phases of Nociception
Transduction: Noxious mechanical, thermal, or chemical stimuli are converted into electrical action potentials at peripheral free nerve endings of primary afferent nociceptors:
A δ A\delta A δ Fibers: Thinly myelinated, medium diameter ( 2 − 5 μ m 2 - 5\text{ }\mu\text{m} 2 − 5 μ m ), conduction velocity 5 − 30 m/s 5 - 30\text{ m/s} 5 − 30 m/s . Mediate rapid, sharp, well-localized "first pain."
C Fibers: Unmyelinated, small diameter ( 0.4 − 1.2 μ m 0.4 - 1.2\text{ }\mu\text{m} 0.4 − 1.2 μ m ), slow conduction velocity 0.5 − 2 m/s 0.5 - 2\text{ m/s} 0.5 − 2 m/s . Mediate delayed, dull, aching, burning "second pain."
Transduction Receptors: Transient Receptor Potential Vanilloid 1 (TRPV1, activated by heat > 43 ∘ C >43^\circ\text{C} > 4 3 ∘ C , protons H + H^+ H + , capsaicin); Acid-Sensing Ion Channels (ASIC); Purinergic P2X/P2Y receptors (activated by extracellular ATP released from ruptured cells); and voltage-gated sodium channels ( Na V 1.7 , Na V 1.8 , Na V 1.9 \text{Na}_V1.7, \text{Na}_V1.8, \text{Na}_V1.9 Na V 1.7 , Na V 1.8 , Na V 1.9 ).
The Inflammatory Soup: Tissue trauma releases a potent cocktail of algogenic substances: bradykinin, prostaglandin E 2 E_2 E 2 ( P G E 2 PGE_2 PG E 2 ), substance P, calcitonin gene-related peptide (CGRP), histamine, serotonin ( 5 -HT 5\text{-HT} 5 -HT ), protons ( H + H^+ H + ), leukotrienes, and nerve growth factor (NGF).
Transmission: Action potentials travel along primary afferent neurons whose cell bodies reside in the dorsal root ganglion (DRG), entering the spinal dorsal horn via the tract of Lissauer. They terminate in Rexed Lamina I (marginal zone) and Rexed Lamina II (substantia gelatinosa) . The presynaptic terminals release excitatory neurotransmitters:
Glutamate: Rapid excitation acting on postsynaptic α \alpha α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ( AMPA ) and kainate receptors.
Substance P & CGRP: Neuropeptides acting on Neurokinin-1 (NK-1) and CGRP receptors, producing slow, sustained excitatory postsynaptic potentials.
Second-order projection neurons decussate obliquely across the anterior white commissure of the spinal cord within 1 to 2 segments and ascend in the contralateral anterolateral quadrant as the Spinothalamic Tract (STT) :
Neospinothalamic Tract: Projects directly to the ventral posterolateral (VPL) nucleus of the thalamus, relaying to primary and secondary somatosensory cortices ( S 1 , S 2 S1, S2 S 1 , S 2 ) to decode sensory-discriminative properties (location, intensity, duration).
Paleospinothalamic Tract: Projects to the medial thalamus, periaqueductal gray, reticular formation, and limbic structures, mediating affective-motivational and autonomic responses.
Modulation: Endogenous pain suppression occurs through descending inhibitory pathways originating from the Periaqueductal Gray (PAG) in the midbrain and the Rostral Ventromedial Medulla (RVM) (including the nucleus raphe magnus). These bulbospinal tracts project down the dorsolateral funiculus to synapse on primary afferents and interneurons in the dorsal horn, releasing:
Norepinephrine: Activates presynaptic and postsynaptic α 2 \alpha_2 α 2 -adrenoceptors, inhibiting calcium influx and hyperpolarizing dorsal horn neurons.
Serotonin ( 5 -HT 5\text{-HT} 5 -HT ): Activates inhibitory interneurons via distinct 5-HT receptor subtypes.
Endogenous Opioid Peptides: β \beta β -endorphin (acts on μ \mu μ -receptors), met- and leu-enkephalin (acts on δ \delta δ -receptors), and dynorphin (acts on κ \kappa κ -receptors), hyperpolarizing neurons by opening inward-rectifying potassium channels and closing voltage-gated calcium channels.
Perception: The conscious subjective experience of pain arising from extensive reciprocal connections between the thalamus, somatosensory cortex, anterior cingulate cortex (ACC) (affective distress), insular cortex (interoception and autonomic integration), and prefrontal cortex.
Peripheral vs. Central Sensitization
Peripheral Sensitization: Prolonged exposure to the "inflammatory soup" phosphorylates transducer channels (TRPV1, Na V 1.8 \text{Na}_V1.8 Na V 1.8 ). This lowers the activation threshold and increases the firing rate of primary nociceptors, producing primary hyperalgesia (exaggerated pain sensitivity strictly confined to the zone of primary tissue trauma).
Central Sensitization and "Wind-Up": Repetitive, sustained high-frequency C-fiber firing triggers continuous glutamate and substance P release into the dorsal horn. Sustained membrane depolarization removes the resting, voltage-dependent magnesium ion ( M g 2 + Mg^{2+} M g 2 + ) block from the pore of the N-methyl-D-aspartate (NMDA) receptor . Calcium ( C a 2 + Ca^{2+} C a 2 + ) pours into the postsynaptic neuron, activating protein kinase C (PKC), calcium/calmodulin-dependent protein kinase II (CaMKII), and neuronal nitric oxide synthase (nNOS). This induces long-term potentiation (LTP) of pain transmission:
Clinical Hallmarks:
Secondary Hyperalgesia: Increased pain sensitivity in undamaged normal tissues surrounding the primary surgical wound.
Allodynia: Perception of pain provoked by normally innocuous stimuli (e.g., light brush of clothing or bedsheets, mediated by low-threshold A β A\beta A β fibers misinterpreting touch as pain due to dorsal horn hyper-responsiveness).
Ketamine's Role: Subanaesthetic ketamine is a non-competitive antagonist of open NMDA receptors, directly blocking the C a 2 + Ca^{2+} C a 2 + pore to abort "wind-up" and reverse central sensitization.
2. The Multimodal Analgesia Paradigm
Multimodal analgesia combines two or more analgesic classes with different mechanisms of action and discrete target receptors within the peripheral and central nervous systems. Rational combinations produce additive or synergistic analgesia while lowering individual drug doses, achieving an opioid-sparing effect of 30 − 50 % 30 - 50\% 30 − 50% and drastically curbing Opioid-Related Adverse Events (ORAEs):
- Postoperative nausea and vomiting (PONV)
- Paralytic ileus and delayed return of bowel motility
- Sedation and life-threatening respiratory depression
- Urinary retention and pruritus
- Long-term physical dependence and opioid-induced hyperalgesia (OIH)
3. Systemic Non-Opioid Pharmacological Modalities +-----------------------------------------------------------------------------------------------------+
- | MULTIMODAL NON-OPIOID PHARMACOTHERAPY |
- | |
- | Drug Class Agent & Dosing Primary Mechanism Key Traps & Constraints |
- | ---------------- ----------------------- --------------------------- ------------------------- |
- | Paracetamol 1 g IV/oral q6h Central COX inhibition; Max 4 g/24h; reduce in |
- | (scheduled baseline) AM404 active metabolite; severe hepatic failure or |
- | cannabinoid CB1/TRPV1 chronic malnutrition |
- | |
- | NSAIDs / COX-2 Ketorolac 15-30 mg IV; Peripheral & central COX Avoid in CKD, hypovolemia, |
- | Inhibitors Celecoxib 200-400 mg PO inhibition; blocks PGE2; active peptic ulcers, GI |
- | reduces opioid use 30-40% bleed, bone fusion surgery |
- | |
- | IV Lidocaine 1-1.5 mg/kg bolus, then Voltage-gated Na+ blockade; ALLEGRO 2025: no ileus gain|
- | Infusion 1.5-2 mg/kg/h IV anti-inflammatory; modest toxic > 5 mcg/mL; avoid |
- | opioid-sparing effect concurrent regional blocks |
- | |
- | Low-Dose 0.25-0.5 mg/kg bolus, Non-competitive NMDA Inhibits central wind-up; |
- | Ketamine then 0.1-0.25 mg/kg/h receptor channel blocker ideal for opioid-tolerant; |
- | minimal psychomimetic dose |
- | |
- | Dexamethasone 4 - 8 mg IV at induction Inhibits phospholipase A2; Dual anti-PONV and opioid |
- | suppresses cytokines sparing; mild hyperglycemia|
- +-----------------------------------------------------------------------------------------------------+
- Paracetamol (Acetaminophen)
Mechanisms: Central inhibition of cyclooxygenase (COX-1, COX-2, and putative COX-3/COX-1b splice variants); active central metabolite N N N -arachidonoylphenolamine ( AM404 ) stimulates cannabinoid C B 1 CB_1 C B 1 receptors and inhibits cellular anandamide reuptake; reinforces descending bulbospinal serotonergic pathways.
Dosing & Clinical Role: Administered as a scheduled baseline: 1 g 1\text{ g} 1 g IV or oral every 6 hours (maximum 4 g/24h 4\text{ g/24h} 4 g/24h in adults > 50 kg > 50\text{ kg} > 50 kg ; reduced to 2 − 3 g/24h 2 - 3\text{ g/24h} 2 − 3 g/24h in severe hepatic impairment, malnutrition, or chronic alcoholism).
NSAIDs and Selective COX-2 Inhibitors
Mechanisms: Inhibit cyclooxygenase enzymes, preventing the conversion of arachidonic acid to prostaglandin H 2 H_2 H 2 ( P G H 2 PGH_2 PG H 2 ), blunting P G E 2 PGE_2 PG E 2 and P G I 2 PGI_2 PG I 2 synthesis to eliminate peripheral nociceptive sensitization and spinal inflammatory wind-up. Reduces opioid consumption by 30 − 40 % 30 - 40\% 30 − 40% .
Non-Selective NSAIDs vs. Selective COX-2 Inhibitors:
Non-selective (Ketorolac, Ibuprofen, Diclofenac): Inhibit both COX-1 (constitutive, produces cytoprotective gastric mucus and thromboxane A 2 A_2 A 2 in platelets) and COX-2 (inducible by cytokines at surgical injury sites). Inhibit platelet aggregation; increase surgical bleeding risk.
Selective COX-2 Inhibitors (Celecoxib, Parecoxib): Selectively inhibit inducible COX-2, leaving platelet COX-1 uninhibited (zero impact on platelet aggregation and bleeding time; reduced gastrointestinal ulceration risk).
Contraindications and Organ Toxicities:
Renal: Prostaglandins ( P G E 2 , P G I 2 PGE_2, PGI_2 PG E 2 , PG I 2 ) maintain vasodilatory perfusion of afferent renal arterioles in hypovolemic or compromised states. NSAIDs precipitate acute kidney injury (prerenal vasoconstriction and acute tubular necrosis) in hypovolemia, dehydration, or pre-existing chronic kidney disease ( G F R < 30 mL/min GFR < 30\text{ mL/min} GFR < 30 mL/min ). Avoid in unstable hemodynamics.
Bone Healing: Prostaglandins stimulate osteoblastic differentiation. NSAIDs are controversial or contraindicated in high-risk spinal fusion surgery or non-union fracture repair.
Intravenous Lidocaine Infusion
Mechanisms: Systemic local anaesthetic infusion blocks open and inactivated voltage-gated sodium channels ( Na V \text{Na}_V Na V ) in primary afferents; suppresses aberrant ectopic neural discharges; attenuates inflammatory cytokine cascade release (IL-1, IL-6, TNF- α \alpha α ); inhibits neutrophil priming and lysosomal enzyme degranulation.
Dosing Regimen: Intravenous loading bolus of 1.0 − 1.5 mg/kg 1.0 - 1.5\text{ mg/kg} 1.0 − 1.5 mg/kg (based on ideal body weight) administered over 10 − 15 minutes 10 - 15\text{ minutes} 10 − 15 minutes at induction of anaesthesia, followed by a continuous infusion of 1.5 − 2.0 mg/kg/h 1.5 - 2.0\text{ mg/kg/h} 1.5 − 2.0 mg/kg/h maintained intraoperatively and continued for up to 24 − 48 hours 24 - 48\text{ hours} 24 − 48 hours postoperatively.
Clinical Indications & Evidence: Earlier small trials and meta-analyses suggested faster return of bowel function after colorectal surgery. However, the large multicentre ALLEGRO trial (Paterson et al., JAMA 2025) found that perioperative IV lidocaine did not improve the return of gastrointestinal function at 72 hours compared with placebo, so routine use to prevent ileus is no longer supported. It may still be considered as an opioid-sparing adjunct when regional techniques are not possible.
Safety & Toxicity Monitoring: Therapeutic plasma concentrations range between 1.5 − 5.0 μ g/mL 1.5 - 5.0\text{ }\mu\text{g/mL} 1.5 − 5.0 μ g/mL . Toxicity ( > 5.0 μ g/mL > 5.0\text{ }\mu\text{g/mL} > 5.0 μ g/mL ) presents sequentially with perioral paresthesia, metallic taste, tinnitus, lightheadedness, slurred speech, visual disturbances, tremors, seizures, and cardiovascular collapse. Critical Safety Rule: Strictly avoid concurrent therapeutic continuous peripheral nerve blocks or high-volume regional local anaesthetic infiltrations while systemic IV lidocaine is infusing, as the cumulative local anaesthetic dose increases the risk of LAST.
Low-Dose Ketamine
Mechanisms: Non-competitive NMDA receptor open-channel antagonist. Blocks the calcium pore, prevents spinal dorsal horn wind-up, attenuates acute opioid tolerance, and prevents opioid-induced hyperalgesia (OIH).
Dosing: IV bolus of 0.25 − 0.5 mg/kg 0.25 - 0.5\text{ mg/kg} 0.25 − 0.5 mg/kg at induction, followed by an infusion of 0.1 − 0.25 mg/kg/h 0.1 - 0.25\text{ mg/kg/h} 0.1 − 0.25 mg/kg/h ( 2 − 4 μ g/kg/min 2 - 4\text{ }\mu\text{g/kg/min} 2 − 4 μ g/kg/min ) discontinued at skin closure or continued for 24 hours 24\text{ hours} 24 hours .
Target Population: Highly effective in major painful surgeries (thoracotomy, major spinal reconstruction, upper abdominal surgery) and essential in opioid-tolerant chronic pain patients .
Alpha-2 Adrenoceptor Agonists
Clonidine & Dexmedetomidine: Highly selective α 2 \alpha_2 α 2 -agonists acting on presynaptic and postsynaptic receptors in the locus coeruleus and substantia gelatinosa. Inhibit substance P release and blunt sympathetic outflow, providing "cooperative sedation" without respiratory depression, while reducing postoperative opioid requirements. Side effects include dose-dependent bradycardia, hypotension, and dry mouth.
Dexamethasone
Mechanisms: Glucocorticoid receptor activation inhibits phospholipase A 2 A_2 A 2 via lipocortin induction, halting arachidonic acid liberation and cytokine transcription.
Dosing: 4 − 8 mg 4 - 8\text{ mg} 4 − 8 mg IV administered at induction. Provides potent, dual-purpose PONV prophylaxis and sustained opioid-sparing somatic analgesia , while prolonging the duration of peripheral nerve blocks when administered intravenously or perineurally.
4. Patient-Controlled Analgesia (PCA) Regimens and Safety
Patient-Controlled Analgesia allows patients to self-administer small, pre-programmed intravenous doses of an opioid on demand. Peak efficacy and patient safety require precise parameter programming:
PCA Parameter Clinical Definition Typical Morphine Protocol Typical Fentanyl Protocol
Demand Dose (Bolus) Quantity of opioid delivered per successful patient trigger 1.0 − 1.5 mg 1.0 - 1.5\text{ mg} 1.0 − 1.5 mg 10 − 20 μ g 10 - 20\text{ }\mu\text{g} 10 − 20 μ g
Lockout Interval Mandatory refractory period preventing further delivery while drug circulates and reaches peak brain effect 5 − 10 minutes 5 - 10\text{ minutes} 5 − 10 minutes 3 − 5 minutes 3 - 5\text{ minutes} 3 − 5 minutes
Background (Basal) Rate Continuous hourly infusion independent of patient demand STRICTLY 0 mg/h in opioid-naive patients! STRICTLY 0 mcg/h in opioid-naive patients!
Dose Limit Maximum cumulative drug permitted within a 1- or 4-hour window 10 − 15 mg 10 - 15\text{ mg} 10 − 15 mg per 4 hours 150 − 200 μ g 150 - 200\text{ }\mu\text{g} 150 − 200 μ g per 4 hours
- Caution
- Critical PCA Danger: Continuous Basal Infusions
Adding a continuous background basal infusion to an IV PCA in opioid-naive patients does NOT improve analgesia, sleep quality, or patient satisfaction. Instead, it increases the risk of nocturnal hypoxemia, respiratory depression, and overdose . Continuous basal infusions are strictly reserved for verified opioid-tolerant patients requiring maintenance baseline substitution.
Sedation Monitoring: The Earliest Predictor of Toxicity
Respiratory rate alone is an insensitive and dangerously late indicator of opioid-induced respiratory depression. Arterial hypercapnia and somnolence precede bradypnea. Sedation scoring using standardized scales (such as the Pasero Opioid-Induced Sedation Scale - POSS ) must be monitored regularly:
S: Sleep, easy to arouse (acceptable).
1: Awake and alert (acceptable).
2: Slightly drowsy, easily aroused (acceptable).
3: Frequently drowsy, drifts off to sleep during conversation ( UNACCEPTABLE ; stop PCA immediately, administer oxygen, notify physician, decrease opioid dose by 50 % 50\% 50% ).
4: Somnolent, minimal or no response to verbal/physical stimulation ( EMERGENCY ; stop PCA, initiate immediate bag-mask ventilation, administer incremental titrated IV naloxone 40 − 100 μ g 40 - 100\text{ }\mu\text{g} 40 − 100 μ g until awake).
5. Enhanced Recovery After Surgery (ERAS) Protocols
Enhanced Recovery After Surgery (ERAS) is an evidence-based, multimodal, multidisciplinary perioperative care pathway designed to blunt the surgical neuroendocrine stress response, preserve physiological organ reserve, minimize postoperative complications, and accelerate functional recovery. [ ERAS PERIOPERATIVE CONTINUUM ]
- |
- +-----------------------------------------+-----------------------------------------+
- | | |
- [ PREOPERATIVE ] [ INTRAOPERATIVE ] [ POSTOPERATIVE ]
- Preadmission counseling - Thoracic epidural (T8-T10 for open) - Early oral fluids & nutrition
- Smoking/alcohol cessation >= 4 wks - Multi-plane fascial blocks (lap) within 4 to 6 hours
- Optimized nutritional status - Multimodal opioid-sparing analgesia - Scheduled non-opioid analgesia
- Carbohydrate loading (clear liquids - Goal-directed fluid therapy (GDFT) - Early mobilization out of bed
- up to 2h pre-induction) using dynamic parameters (SVV/PPV) on day of surgery (> 2h)
- Avoidance of prolonged fasting - Active warming (normothermia > 36°C) - Early urinary catheter removal
- Avoidance of mechanical bowel prep - Avoidance of routine drains/NG tubes (< 24-48 hours)
- Core Elements Across the Perioperative Phases
Preoperative Phase:
Preadmission Education & Prehabilitation: Setting realistic expectations regarding pain, functional milestones, and discharge criteria.
Smoking and Alcohol Cessation: Minimum of 4 weeks prior to elective surgery to restore mucociliary clearance and immune function.
Carbohydrate Loading & Fasting Guidelines: Fasting from solid food for 6 hours; unrestricted ingestion of clear fluids containing complex carbohydrates (maltodextrin 800 mL 800\text{ mL} 800 mL evening prior, 400 mL 400\text{ mL} 400 mL up to 2 hours before induction ). This transitions the patient from a catabolic, insulin-resistant fasting state into an anabolic, fed state, reducing postoperative insulin resistance by 50 % 50\% 50% , preserving skeletal muscle mass, and alleviating thirst, anxiety, and hunger.
Avoidance of Mechanical Bowel Preparation: Routine oral bowel preparation causes severe dehydration, electrolyte derangements, and mucosal inflammation, and is omitted in colonic surgery.
Intraoperative Phase:
Surgical Access & Technique: Laparoscopic or robotic minimally invasive surgery whenever feasible to minimize tissue trauma and cytokine release.
Neuraxial & Regional Analgesia: Low-thoracic epidural analgesia ( T8 - T10 ) with low-dose local anaesthetic and lipophilic opioids for major open abdominal laparotomies; provides profound analgesia, blocks splanchnic sympathetic tone, and reduces ileus. For laparoscopic cases, multi-modal fascial plane blocks (TAP, ESP, rectus sheath) are favored.
Goal-Directed Fluid Therapy (GDFT): Restrictive or goal-directed balanced crystalloid administration utilizing dynamic stroke volume variation ( S V V SVV S VV ) or pulse pressure variation ( P P V PPV PP V ) guided by arterial waveform analysis or esophageal Doppler. Prevents both hypervolemia (which produces intestinal edema, impaired anastomotic healing, and pulmonary complications) and hypovolemia (renal hypoperfusion).
Maintenance of Normothermia: Active forced-air warming to maintain core temperature > 36.0 ∘ C > 36.0^\circ\text{C} > 36. 0 ∘ C , preventing hypothermia-induced coagulopathy, surgical site infections, and shivering-induced myocardial strain.
Avoidance of Routine Nasogastric Tubes and Peritoneal Drains: Unnecessary NGTs increase atelectasis, aspiration, and pneumonia; prophylactic surgical drains do not prevent anastomotic leaks and hinder early ambulation.
Postoperative Phase:
Early Enteral Nutrition: Reintroduction of oral fluids and regular solid food within 4 − 6 hours 4 - 6\text{ hours} 4 − 6 hours postoperatively; stimulates coordinated gastrointestinal peristalsis and mucosal healing.
Early Ambulation: Mobilization out of bed into a chair on the day of surgery, progressing to walking > 2 − 4 hours/day > 2 - 4\text{ hours/day} > 2 − 4 hours/day on postoperative day 1; prevents deep vein thrombosis, preserves skeletal muscle, and expands functional residual capacity ( F R C FRC FRC ).
Early Catheter Removal: Urinary Foley catheters removed within < 24 − 48 hours < 24 - 48\text{ hours} < 24 − 48 hours postoperatively to reduce catheter-associated urinary tract infections (CAUTI) and unencumber patient mobility.
Proactive Multimodal PONV Prophylaxis: Routine dual- or triple-agent prophylaxis (dexamethasone 4 − 8 mg 4 - 8\text{ mg} 4 − 8 mg , ondansetron 4 mg 4\text{ mg} 4 mg , droperidol 0.625 mg 0.625\text{ mg} 0.625 mg ) tailored to Apfel risk scores.